Morgan Bayer

Patients in the real world with unresectable or metastatic urothelial carcinoma has improved OS with Padcev: © JAEMIN - stock.adobe.com.

Among patients in the real-world setting with unresectable or metastatic urothelial carcinoma, treatment with Padcev (enfortumab vedotin) in the third line significantly improved overall survival (OS) , according to data from the EV-301 trial which were presented at the 

2025 ASCO Genitourinary Cancers Symposium

“We aimed to investigate the efficacy and safety of Padcev in patients with unresectable or metastatic urothelial carcinoma in real-world practice,” investigators stated in a poster presentation during the meeting. “The retrospective design is a limitation.”

Overall survival (OS): the amount of time a patient survives after being diagnosed with or starting treatment for a disease.

Progression-free survival (PFS): the amount of time a patient lives with a disease without it worsening.

In the study, 419 patients with unresectable or metastatic urothelial carcinoma received treatment from April 2004 to April 2024. Patients who received the following treatments were stratified into three treatment groups: first-line chemotherapy and sequential chemotherapy alone (chemo-alone group), maintenance or second-line immunotherapy after first-line chemotherapy (chemo/ICI group; 217 patients) and Padcev after first-line chemotherapy and immunotherapy (chemo/ICI/Padcev group; 115 patients).

The primary end point in the trial was the comparison of first-line progression-free survival (PFS) and OS between these three treatment groups and secondary end points focused on skin-related side effects regarding efficacy and safety in the chemo/ICI/Padcev group.

Investigators noted that OS was significantly longer in the chemo/ICI/Padcev group; however, there was no significant difference in first-line PFS of first-line therapy between the three groups. The unadjusted OS from first-line therapy was 36 months in the chemo/ICI/Padcev group, 25 months in the chemo/ICI group and 16 months in the chemo-alone group. The chemo/ICI/Padcev group was significantly associated with improved OS, according to the investigators.

The average age in the chemo-alone group was 67 years, 72 years in the chemo/ICI group and 74 years in the chemo/ICI/Padcev group and most patients were male: 73%, 78% and 72%, respectively. Ten percent of patients in the chemo/ICI/Padcev group had a ECOG performance status greater than 1; this information was not documented for the other 2 groups.

There were 39% of patients with upper tract urothelial carcinoma (UTUC) in the chemo-alone group, 61% in the chemo/ICI group and 45% in the chemo/ICI/Padcev group. Lymph node metastases were present in 70% in the chemo-alone group, 60% in the chemo/ICI group and 47% in the chemo/ICI/Padcev group and distant metastases were present in 76%, 67% and 70%, respectively. In addition, liver metastases were present in 11%, 12% and 13%, respectively.

In the chemo-alone group, 62% of patients received local therapy (54 underwent surgery and none received radiation). In the chemo/ICI group, 53% of patients received local therapy (94 underwent surgery and 18 received radiation). In the chemo/ICI/Padcev group, 59% of patients received local therapy (55 underwent surgery and 13 received radiation).

Seventy-six percent of patients in the chemo-alone group received a first-line carboplatin-based regimen, compared with 64% in both the chemo/ICI and chemo/ICI/Padcev groups. In the chemo/ICI and chemo/ICI/Padcev groups, 21% of patients each received Bavencio (avelumab) and there were no patients who did in the chemo-alone group.

Investigators noted that patients with skin-related side effects (69 patients) had significantly longer PFS and OS than those without (46 patients). In addition, a significant association between skin-related side effects and prolonged relapse-free survival and OS was observed.

The median PFS from Padcev treatment was 9.7 months for those with skin-related side effects and 5.9 months in those without. The median OS from Padcev treatment was 19 months versus 14 months, respectively. The number of cycles of Padcev treatment was seven for those with skin-related side effects and four for those without.

Padcev dose levels varied among patients, with the majority of patients with skin-related side effects receiving the 1.25 mg/kg dose in cycle 1. In contrast, the majority of patients without skin-related side effects received a dose of 1.25 mg/kg on cycle 10. However, overall patients without skin-related side effects received higher doses of Padcev throughout the 10 cycles of treatment whereas those with skin-related side effects had higher doses earlier on in the treatment course. Dose reductions occurred in 67% of patients with skin-related side effects and 35% in those without.

Patient Characteristics Related to Side Effects

The average age of patients with and without skin-related side effects was 74 years and most patients were male (67% with skin-related side effects versus 80% without). The body mass index for patients with skin-related side effects was 21.9 and 21.3 for those without. Those with an ECOG performance score greater than 1 was 7% in those with skin-related side effects and 65% in those without.

The percentage of those with UTUC and skin-related side effects was 49% and 39% in those without skin-related side effects. T4 TMN staging was observed in 30% versus 33%, lymph node metastases in 49% versus 50% and distant metastases in 68% versus 72%, each respectively. In addition, liver metastases were observed in 13% of patients with skin-related side effects and without and 64% versus 76% had chronic kidney disease stage 3, respectively.

Treatment History Related to Side Effects

Fifty-seven percent of patients with skin-related side effects had local therapy (32 patients had surgery and seven received radiation) and 63% of patients without skin-related side effects (23 patients had surgery and six received radiation). Those receiving carboplatin-based regimens were 68% and 59%, respectively. There were 14% of patients with skin-related side effects who received prior avelumab and 77% who received prior Keytruda (pembrolizumab). This percentage was 30% and 74%, respectively, in those without skin-related side effects.

“Although skin side effects often led to dose reductions, dose adjustment of Padcev may be the key for long-term use and optimizing outcomes,” investigators stated.

“Real-world analysis of the efficacy and safety of enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma: A multicenter retrospective study” by Dr. Shingo Hatakeyama, et al., 

For more news on cancer updates, research and education, don’t forget to 

subscribe to CURE®’s newsletters here.

Articles

Padcev (enfortumab vedotin) significantly improved overall survival (OS) in patients with unresectable or metastatic urothelial carcinoma in a real-world setting, as demonstrated by the EV-301 trial. The study involved 419 patients stratified into three treatment groups, with the chemo/ICI/Padcev group showing the longest OS. Skin-related side effects were associated with longer progression-free survival (PFS) and OS, suggesting that dose adjustments of Padcev could optimize outcomes. The retrospective design of the study was noted as a limitation by the investigators.

Among patients in the real world with unresectable or metastatic urothelial carcinoma, Padcev significantly improved overall survival outcomes.

Padcev Significantly Improves OS in Real-World Urothelial Carcinoma

Real-world data compared treatment with three CDK4/6 inhibitors in HR-positive, HER2-negative metastatic breast cancer. 

When comparing three CDK4/6 inhibitor combinations during the initial treatment for hormone receptor (HR)-positive, HER2-negative metastatic (spreading) breast cancer, no significant overall survival (OS) advantage was found, as presented during the 

2024 San Antonio Breast Cancer Symposium (SABCS)

“To date, we have no head-to-head phase 3 studies comparing the CDK4/6 inhibitors,” noted Dr. Kari B. Wisinski, professor of medicine at the University of Wisconsin Carbone Cancer Center in Madison, Wisconsin, in a presentation of the data.

The median follow-up was 33 months for the Ibrance (palbociclib) plus an aromatase inhibitor (AI; 6,831 patients) group, 16 months for the Kisqali (ribociclib) plus AI (1,279 patients) group and 21 months for the Verzenio (abemaciclib) plus AI (1,036 patients) group.

Overall survival (OS): time from diagnosis or treatment start until death from any cause.

Progression-free survival (PFS): time during which the disease does not worsen.

Neutropenia: low levels of neutrophils, a type of white blood cell.

Thrombocytopenia: low levels of platelets in the blood, which may cause easy bruising or bleeding.

Primary end point: the main objective measured at the end of the study to see if treatment worked.

Real-world data was used from a retrospective study analyzing 9,146 patients from 280 US sites. The study investigators compared OS rates between treatment groups.

The median OS before an unadjusted analysis in the Ibrance plus AI group was 54.4 months, 60.3 months in the Kisqali plus AI group and not reached (NR) in the Verzenio plus AI group. When an OS is not reached, it means not enough patients in the respective group died at the time of data collection. The OS rates in the Ibrance plus AI group at 12, 24 and 30 months were 89.6%, 77.4% and 71.4%, respectively. For the Kisqali plus AI group, these OS rates were 90%, 78% and 73.3%. In the Verzenio plus AI group, the OS rates were at 12, 24 and 30 months were 88.4%, 76.1% and 71.5%.

After applying the adjusted analysis, the median OS for the Ibrance plus AI group was 54.6, 59 months for the Kisqali plus AI group and 64.5 months for the Verzenio plus AI group. The OS rates at 12, 24 and 30 months for the Ibrance plus AI group were 89.7%, 77.5% and 71.4%, respectively. These were 89.2%, 77.3% and 72.2% for the Kisqali plus AI group, respectively. For the Verzenio plus AI group, the OS rates were 88.2%, 76.1% and 71.5%, respectively.

Also in the adjusted analysis, 3,714 deaths were reported across all three groups: 3,096 in the Ibrance plus AI group (45.3%), 328 in the Kisqali plus AI group (25.6%) and 290 in the Verzenio plus AI group (28%). The median follow-up duration in group 1 was 33 months, 15.7 months in the Kisqali plus AI group and 21.5 months in the Verzenio plus AI group.

Regarding side effects, there were higher rates of neutropenia in the Ibrance plus AI group (67%) than the Kisqali plus AI group (60%) and the Verzenio plus AI group (21.9%). However, anemia was greater in the Ibrance plus AI group (5.4%) and the Verzenio plus AI group (6%) versus the Kisqali plus AI group (0.9%). Thrombocytopenia was consistent across the three groups: 1.6% for the Ibrance plus AI group, 0.9% for the Kisqali plus AI group and 1.9% for the Verzenio plus AI group.

“Now there are some limitations for this analysis. The [Ibrance plus AI] and [Verzenio plus AI] cohorts had smaller numbers and shorter follow-ups, and the point estimates were relatively (or possibly) unstable after 30 months. In addition, as always with real-world analysis, there is potential for unmeasured confounders,” Wisinski noted.

Wisinski applied these real-world data to the following phase 3 trials: PALOMA-2, MONALEESA-2, MONALEESA-3, MONALEESA-7 and MONARCH-3.

The primary end point for each study was progression-free survival (PFS), and all three demonstrated benefit, Wisinski explained. When comparing the median OS, Wisinski stated that “median OS has been improved with the addition of [Kisqali], [Verzenio] demonstrated a clinical meaningful benefit but it was not statistically significant, and [Ibrance] did not provide benefit.” In the real-world analysis the median OS rates were quite consistent with what was observed in these studies, Wisinski added.

Patients included in the trial had HR-positive, HER2-negative metastatic breast cancer, were 18 years or older and started index treatment with either Ibrance plus AI, Kisqali plus AI or Verzenio plus AI.

“The P-VERIFY study suggests that there is no difference in OS among first-line CDK4/6 inhibitors and this would align with the PFS data that we have from those first-line studies,” Wisinski concluded. “However, the statistically OS beneficent that we have seen as only been with [Kisqali]. I think that longer follow-up would be very valuable and although real-world analyses have limitations it is unlikely that we will have a head-to-head study, and thus, these data add to the information that we have.”

“Comparative Overall Survival of CDK4/6 Inhibitors Plus an Aromatase Inhibitor (AI) in HR+/HER2– MBC in the US Real-World Setting.” By Dr. Hope S. Rugo, et al. Presented at the San Antonio Breast Cancer Symposium, San Antonio, Abstract PS2-03.

The comparison of three CDK4/6 inhibitor combinations for HR-positive, HER2-negative metastatic breast cancer revealed no significant overall survival (OS) advantage among them. Real-world data from 9,146 patients showed median OS rates of 54.6 months for Ibrance, 59 months for Kisqali, and 64.5 months for Verzenio. Side effects varied, with higher neutropenia in the Ibrance group. Limitations include smaller cohorts and potential confounders. The findings align with phase 3 trials, indicating no OS difference among first-line CDK4/6 inhibitors, except for Kisqali showing statistical OS benefit.

No significant survival benefits were found when comparing three CDK4/6 inhibitor combinations during initial treatment for HR-positive, HER2-negative metastatic breast cancer.

CDK4/6 Inhibitor Combos Miss Survival Goal in Metastatic Breast Cancer Subset

Treatment with Jaypirca was shown to reduce treatment discontinuations in patients with CLL or SLL. 

Among patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Jaypirca (pirtobrutinib) demonstrated superior progression-free survival (PFS) and low rates of treatment discontinuation versus the investigator’s choice of treatment, according to findings from the prospective phase 3 BRUIN CLL-321 trial, presented at the 

In the study, patients with CLL or SLL were randomly assigned to receive Jaypirca monotherapy (119 patients) or Zydelig (idelalisib) plus Rituxan (rituximab) or bendamustine plus Rituxan (119 patients; IdelaR/BR). The primary end point was PFS and was met at the trial’s primary analysis in August 2023. The secondary end point was overall survival (OS) with a final analysis in August 2024.

At a median follow-up of 19.4 months, patients in the Jaypirca group had a median PFS of 14 months. At a median follow-up of 17.7 months, patients in the idelaR/BR group had a median PFS of 8.7 months. The independent review committee (IRC) reported that Jaypirca reduced the risk of progression or death by 46%.

Event-free survival (EFS): time until a patient experiences disease progression, death or a specific event.

Progression-free survival (PFS): time until a patient's disease worsens or death.

Overall survival (OS): time a patient lives after a diagnosis, regardless of disease status, until death by any cause.

The investigator-assessed PFS showed that at a median follow-up of 19.4 months, median PFS was 15.3 months in the treatment group versus 9.2 months in the control group at a median follow-up of 17.5 months. Jaypirca reduced the risk of progression or death by 52% in the investigator assessment.

“The investigator assessment of PFS was consistent with the independent review committee,” Dr. Jeff P. Sharman, director of research, Williamette Valley Cancer Institute, and medical director of hematology research at the US Oncology Network, in Eugene, Oregon, said during a presentation of the data at the meeting.

The safety profile for the Jaypirca was consistent with prior phase 1 and 2 trials. Treatment-related side effects led to discontinuation in 5.2% of patients who received Jaypirca versus 21.1% among patients who received IdelaR/BR treatment. When adjusting for exposure, the incidence rate of treatment-emergent side effects was lower with Jaypirca compared with IdelaR/BR.

Investigators also evaluated side effects of special interest (AESI) that are common to BTK inhibitors. Any-grade hypertension was reported in 6.9% of patients and grade 3 (severe) or worse was reported in 2.6% of patients. “Although patients with atrial arrhythmias were not excluded from the trial, cumulative event rates were low,” Sharman said. “Furthermore, two of the three subjects with treatment emergent atrial fibrillation had a prior history,” he continued.

Jaypirca was also favored in event-free survival (EFS). At a median follow-up of 19.4 months, the experimental group had a median EFS of 14.1 months versus 7.6 months in the control group at a median follow-up of 18.7 months. Jaypirca reduced the risk of an event by 61%.

“The event-free survival end point captures not only progression and death, but also discontinuations for toxicity, and thus better captures the integrated efficacy and safety of the intervention,” Sharman said.

The time to next treatment (TTNT) or death was also evaluated. At a median follow-up of 20 months, the experimental group demonstrated a median TTNT of 24 months versus 10.9 months in the control group at a median follow-up of 20.2 months. Jaypirca reduced the risk of starting next treatment or death by 63% with a median TTNT of about 24 months. “This captures the overall efficacy of the treatment as patients with IRC-determined asymptomatic radiographic progressions who are benefitting from therapy were not mandated to discontinue treatment,” Sharman said.

When TTNT was stratified by prior exposure to Venclexta (venetoclax), patients who received Jaypirca but were naïve to the BCL2 inhibitor (59 patients/group) had a median TTNT of 29.5 months versus 12.5 months for those who received IdelaR/BR. In patients who were previously treated with venetoclax (60 patients/group), the median TTNT was 20 months in the treatment group versus 8.7 months in the control group.

“[Jaypirca] was able to delay subsequent treatment or death for 2.5 years in patients who were naive to venetoclax, demonstrating that continued BTK inhibition can be an effective strategy after failure of first- or second-generation BTK agents,” Sharman said.

Although OS was evaluated, the study was not powered to detect the difference between the two groups, noted Sharman. Further, the analysis was confounded because 76% of patients were allowed to cross over post-progression.

PFS among clinical subgroups also demonstrated a consistent benefit in favor of Jaypirca and this was observed across molecular characteristics, including TP53 status, complex karyotype and IGHV status.

“[Jaypirca] is an effective, well-tolerated agent in patients with difficult-to-treat disease and provides a clinically meaningful way to sustain BTK inhibition,” Sharman concluded.

“BRUIN CLL-321: Randomized phase III trial of Jaypirca versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma” By Dr. Sharman JP, et al., 

Jaypirca (pirtobrutinib) demonstrated superior progression-free survival (PFS) and lower treatment discontinuation rates compared to standard treatments in patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The phase 3 BRUIN CLL-321 trial showed Jaypirca reduced the risk of progression or death by 46% to 52% and had a favorable safety profile. Event-free survival (EFS) and time to next treatment (TTNT) were also improved with Jaypirca, highlighting its efficacy and tolerability in difficult-to-treat cases.

Jaypirca showed superior progression-free survival and lower discontinuation rates versus standard treatments in patients with previously treated CLL or SLL.

Treatment Discontinuations Reduced With Jaypirca in CLL, SLL

Navtemadlin, a novel MDM2 inhibitor, reduced biomarkers of disease severity in patients with relapsed or refractory myelofibrosis, according to data presented at the 2024 ASH Annual Meeting.

Patients with relapsed or refractory (R/R) myelofibrosis experienced reduced biomarkers of disease severity following treatment with the novel p53 potentiating anticancer agent best-in-class MDM2 inhibitor navtemadlin (KRT-232), which suggested that the agent may target disease-driving cells and alter its progression, according to data from the phase 3 BOREAS trial that were presented at the 2024 ASH Annual Meeting.

“I want to emphasize the biology that drives this approach. The MDM2 is a negative regulator of wild-type p53, which is a master determinant of self-fate, and this becomes very critical when you consider its influence over the four hallmarks of myelofibrosis: CD34-positive MF cell proliferation, MF driver gene variant allele frequency (VAF), bone marrow fibrosis, and pro-inflammatory cytokines,” said Dr. John O. Mascarenhas during a presentation of the data.

Mascarenhas is professor of medicine, hematology and medical oncology, director, Center of Excellence for Blood Cancers and Myeloid Disorders and director, Adult Leukemia Program at Mount Sinai Tisch Cancer Center in New York.

In the randomized, multicenter, global phase 3 BOREAS trial, navtemadlin monotherapy was compared with best available therapy (BAT) that included hydroxyurea, peginterferon, immunomodulatory imide drugs or supportive care. Those patients included in the trial had TP53 wild-type myelofibrosis and were R/R to a JAK inhibitor. The data cut-off was Sept. 30, 2024.

CD34-positive MF cell proliferation: the increase of cells that express the protein CD34 in a patient with myelofibrosis.

MF driver gene variant allele frequency (VAF): frequency of genetic mutations that are drivers for myelofibrosis.

Bone marrow fibrosis: when bone marrow is replaced with scar tissue.

Pro-inflammatory cytokines: proteins that start or increase inflammation in the body.

In the study, 183 patients were randomly assigned to receive navtemadlin (123 patients) at 240 milligrams for seven days in a row for a 28-day cycle (with 21 days of drug holiday) or one cycle of BAT (60 patients) for 28 days.

“The patients who were on a JAK inhibitor at the time had a 28-day washout period so that from a spleen and symptom perspective they were clear on day 1 of navtemadlin dosing,” Mascarenhas explained.

“What we saw in terms of biomarkers was a very significant, potent, rapid reduction in circulating CD34 cells as a hallmark of MF even within 12 weeks and sustained over 24 and 36 weeks,” Mascarenhas stated. At 12 weeks, CD34+ cells showed a median reduction of 68% from baseline in 50 patients in the treatment arm and 52% in 25 patients in the BAT arm. This trend continued at 24 weeks (48 patients, 70% reduction versus 19 patients, 38% reduction) and at 36 weeks (21 patients, 76% reduction versus nine patients, 33% reduction).

The reduction in driver gene VAF by 50% or greater was observed in 21% (17of 82) of patients in the treatment arm and 12% (four of 33) of patients in the BAT arm at 24 weeks. “So nearly doubling the molecular response at 24 weeks,” Mascarenhas noted.

Mascarenhas also explained that a reduction in driver VAF was observed to be associated with other biological hallmarks or features of the disease, serving as a surrogate biomarker of disease burden. He continued to explain that the decreases in circulating CD34+ cells and driver gene VAF are associated with an increase in spleen volume response (SVR) with navtemadlin treatment.

In addition, improved bone marrow fibrosis was observed with navtemadlin treatment versus BAT at 24 weeks. In the treatment arm, 2% of patients had improved by two grades or greater, 45% had improved by one grade, 30% were stable and 23% worsened. In the BAT arm, 3% had improved by two grades or greater, 21% had improved by one grade, 52% were stable and 24% worsened.

Pro-inflammatory markers were also assayed, and treatment with navtemadlin showed a reduction in serum cytokine levels over a 48-week period, Mascarenhas noted.

Regarding baseline demographics, in the treatment arm 59% had primary MF subtype and 42% had secondary. In the BAT arm 58% had primary MF subtype and 42% had secondary. Regarding driver mutations, JAK2 mutations were observed in 72% of the treatment arm and 65% of the BAT arm; CALR mutations in 18% versus 27%; MPL mutations in 4% versus 2% and triple-negative cases in 6% versus 7%, respectively.

High molecular risk mutations (at least one) were observed in 62% of the treatment arm and 68% of the BAT arm, and high molecular risk mutations (at least two) were seen in 24% and 23%, respectively. ASXL1 mutations were present in 56% versus 60%, and EZH2 mutations in 15% versus 7%, each respectively. Bone marrow fibrosis scores for grades 1, 2 and 3 were 9% versus 10%, 35% versus 35% and 46% versus 37%, respectively. “So, a very advanced patient population who had failed JAK inhibitor therapy upfront,” Mascarenhas summarized.

“The primary end point was SVR35 at 24 weeks,” Mascarenhas said. SVR35 is defined as an SVR of 35% or more from baseline after 24 weeks. Exploratory end points included reduction in the following: CD34+ cell count in peripheral blood, VAF, cytokines and bone marrow fibrosis. Combinations of these were assessed at pre-dose, weeks 12, 24 and then every 12 weeks.

The randomized, double-blinded add-on phase 3 POIESIS study will explore navtemadlin in combination with Jakafi (ruxolitinib) in patients with JAK inhibitor-naive myelofibrosis. Patients will start by taking Jakafi alone during the initial phase, and those who show a suboptimal response are randomly assigned to receive either navtemadlin (120 patients) or placebo (60 patients) in addition to ongoing Jakafi treatment.

The coprimary end points of this study are targeted SVR and total syndrome score reduction at 24 weeks after randomization.

“The BOREAS trial is the first global phase 3 trial, conducted solely in patients with MF who are truly R/R to JAK inhibitor treatment, to report results. Navtemadlin monotherapy has been shown to improve biomarkers of disease burden in this patient population that I would argue is suggestive of anti-clonal activity and disease modification. This includes reduction in CD34 cell, driver mutation burden, serum inflammatory cytokine levels and importantly correlating with SVR, which is a key clinical outcome predictive of quality of life and overall survival,” Mascarenhas said.

“Disease-modifying activity of navtemadlin correlates with clinical responses in a randomized, multicenter, global phase 3 study (BOREAS) in JAK-inhibitor relapsed/refractory myelofibrosis” by Dr. John O. Mascarenhas et al., 

Navtemadlin, a novel MDM2 inhibitor, demonstrated significant efficacy in reducing biomarkers of disease severity in patients with relapsed or refractory myelofibrosis, as shown in the phase 3 BOREAS trial. The study highlighted navtemadlin's potential to target disease-driving cells, leading to reductions in circulating CD34+ cells, driver gene variant allele frequency, and pro-inflammatory cytokines. Improvements in bone marrow fibrosis and spleen volume response were also observed. The trial underscores navtemadlin's potential as a disease-modifying agent in a challenging patient population resistant to JAK inhibitors.

Patients with relapsed or refractory (R/R) myelofibrosis experienced reduced biomarkers of disease severity following treatment with navtemadlin. 

Morgan Bayer

Padcev Significantly Improves OS in Real-World Urothelial Carcinoma

CDK4/6 Inhibitor Combos Miss Survival Goal in Metastatic Breast Cancer Subset

Treatment Discontinuations Reduced With Jaypirca in CLL, SLL

Navtemadlin Shows Biomarker Response in Patients with R/R Myelofibrosis

Latest News